(Q36117718)

English

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib (English)

1 reference

Europe PubMed Central

12 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Karen L. Reckamp

object named as

Karen L Reckamp

10

0 references

object named as

Karen Kelly

4

0 references

David R Gandara

11

object named as

David R Gandara

1 reference

Europe PubMed Central

12 August 2017

6

object named as

Ravi Salgia

1 reference

Europe PubMed Central

12 August 2017

author name string

Primo N Lara

1

1 reference

Europe PubMed Central

12 August 2017

Jeff Longmate

2

1 reference

Europe PubMed Central

12 August 2017

Philip C Mack

3

1 reference

Europe PubMed Central

12 August 2017

Mark A Socinski

5

1 reference

Europe PubMed Central

12 August 2017

Barbara Gitlitz

7

1 reference

Europe PubMed Central

12 August 2017

Tianhong Li

8

1 reference

Europe PubMed Central

12 August 2017

Mariana Koczywas

9

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

23 June 2015

1 reference

Europe PubMed Central

12 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

12 August 2017

21

1 reference

Europe PubMed Central

12 August 2017

19

1 reference

Europe PubMed Central

12 August 2017

4321-4326

1 reference

Europe PubMed Central

12 August 2017

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Epidermal growth factor receptor inhibition in lung cancer: status 2012.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 October 2017

Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

2 July 2018

Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

23 September 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4592395

23 September 2018

Identifiers

10.1158/1078-0432.CCR-14-3281

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36117718&oldid=1629832472"